We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma. Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, which results in irreversible vision loss and potentially blindness. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. Our product candidates, Triple-action Rhopressa™ and Quadruple-action Roclatan™, are once-daily eye drops that, if approved, will provide eye-care professionals with the first novel intraocular pressure-lowering mechanisms of action, or MOA, to treat glaucoma in nearly 20 years.
Apr 25, 2016
Aerie Pharmaceuticals to Announce First Quarter 2016 Financial Results and Host Conference Call on Monday, May 2, 2016
Apr 5, 2016
Aerie Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
View all »Events & Presentations
May 2, 2016 at 5:00 PM ET
Aerie Pharmaceuticals, Inc. First Quarter 2016 Earnings Call